T1	Participants 674 814	patients with locally advanced or metastatic NSCLC who were eligible for bevacizumab, excluding those with predominantly squamous histology.
T2	Participants 1167 1180	1967 patients
T3	Participants 1318 1349	252 patients (12.8%) identified